AD109 reduced obstructive sleep apnea severity by about 44% over 26 weeks in a phase 3 trial of 646 patients who could not tolerate CPAP or refused to use it.
Nearly 42% of patients moved to a lower severity category, and almost 18% no longer showed signs of obstructive sleep apnea by the end of the study.
The nightly pill combines aroxybutynin and atomoxetine to keep upper-airway muscles active during sleep, helping prevent airway collapse; reported side effects were mostly mild, including dry mouth, nausea and insomnia.
CPAP remains the standard treatment, but its bulk and discomfort often hurt adherence, leaving AD109 positioned as a simpler option for a condition affecting nearly 1 billion people worldwide.
The FDA has fast-tracked AD109 for review, with an approval decision expected in 2027.
This breakthrough drug reduces sleep apnea events by half, but is it a cure or a lifelong treatment?
A new sleep apnea pill shows promise, but why did one in five trial participants quit the study?
With an FDA decision looming in 2027, could this new oral pill finally make CPAP machines obsolete?
Transforming OSA Treatment: AD109’s Clinical Impact, Patient Access, and FDA Approval Outlook
Overview
AD109 is an investigational, once-daily oral pill developed by Apnimed Inc. to treat obstructive sleep apnea (OSA), a condition with significant unmet medical needs. The drug is currently moving through the FDA approval process and has received Fast Track designation, which helps speed up the review of treatments for serious conditions. This special status could allow patients to access AD109 sooner. Apnimed has already submitted a New Drug Application, providing the FDA with detailed safety and efficacy data. If approved, AD109 could offer a new, more convenient treatment option for people struggling with OSA.